Recombinant Human Coagulation factor VII/F7 Protein (Yeast)，His

Coagulation factor VII (F7) is a crucial protein in the blood coagulation cascade, playing a key role in the initiation of clot formation. Deficiencies in F7 can lead to bleeding disorders, necessitating the development of therapeutic interventions. The advent of recombinant DNA technology has led to the production of recombinant coagulation factors, including F7, which can provide new treatment options for affected individuals. Research into recombinant factor VII products has gained momentum due to the limitations of traditional treatments, such as plasma-derived products, which may pose risks of viral transmission and allergic reactions. Clinical studies have demonstrated the effectiveness of recombinant F7 in managing bleeding episodes and preventing complications during surgical procedures in patients with hemophilia and F7 deficiency. Furthermore, the use of recombinant proteins allows for higher purity and more consistent dosing, addressing many challenges associated with existing therapies. As our understanding of the coagulation cascade and genetic factors influencing bleeding diatheses evolves, recombinant factor VII continues to be investigated for its potential applications, including in patients with other coagulopathies and trauma-induced coagulopathy. Overall, ongoing research into the safety, efficacy, and novel applications of recombinant F7 aims to enhance patient outcomes and expand therapeutic options in the field of hematology.